| abstract |
Methods have been developed to increase the encapsulation or incorporation of sunitinib in polymeric matrices. The resulting formulations provide more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. On administration, sunitinib or its analog or salt is released over a prolonged period of time in concentrations that are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity. |